MESOBLAST LTD 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Mesoblast reported FY2026 net revenue of $115 million, driven by the first full year U.S. launch of RYONCIL, with fourth-quarter revenue of $36 million. Gross profit on total sales, excluding amortization, was $110 million, and net loss after tax narrowed 44% to $57.5 million. Operating spend increased to support commercialization and Phase 3 programs, including $17.3 million in product development, $21.2 million in R&D, and about $18 million in sales and marketing.

Company Outlook & Strategy: Management said FY2026 marked a transition from an R&D-stage company to a commercial one, and they expect double-digit growth over the next 12 months. The strategy is to expand RYONCIL beyond pediatric acute GvHD into adults with steroid-refractory acute GvHD, rare pediatric inflammatory diseases such as Duchenne muscular dystrophy, and potentially other partnered indications. They also highlighted advancing rexlemestrocel toward blockbuster opportunities in chronic low back pain and inflammatory heart failure.

Key Industry Trends: The call emphasized large unmet needs in rare inflammatory diseases, transplant-related GvHD, chronic low back pain, and advanced heart failure. Management cited expanding FDA pathways for label extensions on approved cell therapies and strong physician interest in alternatives to opioids for chronic pain. Competitive and evidence-generation dynamics were highlighted in Duchenne and adult GvHD.

Operational Highlights: RYONCIL achieved more than 50 U.S. centers onboarded and insurance coverage for over 98% of U.S. lives, supported by a J-Code received in October 2025. Compassionate-use and real-world data showed 84% survival in early pediatric GvHD and 76% day-100 survival in heavily pretreated adult patients. The adult GvHD randomized trial is enrolling across 40+ U.S. sites, the pediatric Duchenne Phase 3 has FDA IND clearance, the chronic low back pain Phase 3 has completed treatment in 350 patients, and the heart failure program continues toward BLA filing.

Challenges & Risks: Management noted that further growth in RYONCIL will depend on deeper penetration of the current pediatric market and successful expansion into adult GvHD. Key execution risks include clinical trial readouts, regulatory approvals, and proving replication of prior efficacy in larger studies. They also acknowledged competition in Duchenne and the need to manage cash while funding multiple late-stage programs.

Key Analyst Questions & Responses: Piper Sandler asked about FY2027 growth and pediatric GvHD penetration; management declined formal guidance but said they expect double-digit growth and will have more visibility by midyear. On Duchenne, management said they prioritized it because earlier intervention in younger children could provide greater benefit than later-stage approaches, despite competition in the field.